Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
Express Scripts
Fish and Richardson
QuintilesIMS
Cantor Fitzgerald
McKesson
Deloitte
US Department of Justice

Generated: November 13, 2018

DrugPatentWatch Database Preview

Rempex Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for REMPEX PHARMS, and when can generic versions of REMPEX PHARMS drugs launch?

REMPEX PHARMS has two approved drugs.

There are four US patents protecting REMPEX PHARMS drugs.

Summary for Rempex Pharms
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Rempex Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes 9,278,105 ➤ Try a Free Trial ➤ Try a Free Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes 8,680,136 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Rempex Pharms VABOMERE meropenem; vaborbactam POWDER;INTRAVENOUS 209776-001 Aug 29, 2017 RX Yes Yes 9,694,025 ➤ Try a Free Trial ➤ Try a Free Trial
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes 9,084,802 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chubb
Johnson and Johnson
Cipla
Harvard Business School
Covington
Daiichi Sankyo
Citi
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.